Poster highlights progress in the ongoing Phase 1/2 clinical trial of RP1 alone & in combination with nivolumab WOBURN, Mass. , May 16, 2019 (GLOBE NEWSWIRE) — Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™